Company: KROS
Filing Date: 2025-08-06
Form Type: 8-K
Source: 0001664710-25-000071
Chunk: 2

Company: Keros Therapeutics, Inc.
Filing Date: 2025-08-06
Form: 8-K
Item: Item 5.02
Chunk 2
---
 including damages, judgments, fines, penalties, settlements and costs and attorneys’ fees and disbursements, incurred in any claim, action or proceeding arising in her capacity as an executive officer or in connection with service at the Company’s request for another corporation or entity.

Departure of Christopher Rovaldi as President and Chief Operating Officer

On August 6, 2025, the Company announced that Christopher Rovaldi will cease serving as the President and Chief Operating Officer of the Company, effective as of August 18, 2025 (the “ Separation Date”).

In connection with the cessation of his employment, Mr. Rovaldi has entered into a separation and release agreement with the Company, effective as of August 18, 2025 (the “ Separation Agreement”). Pursuant to the Separation Agreement, Mr. Rovaldi will provide up to 20 hours of consulting services to the Company for the three-month period following the Separation Date until November 18, 2025 (the “ Consulting Period”). As consideration for his consulting services in excess of 20 hours during the Consulting Period, the Company will pay Mr. Rovaldi an hourly fee of $425.00. In addition, the Company will provide Mr. Rovaldi with (a) cash severance equivalent to nine months of Mr. Rovaldi’s base salary in effect as of the Separation Date, (b) reimbursement of COBRA healthcare premium costs for the same level of coverage he had during employment until the earlier of (i) nine months, (ii) the expiration of Mr. Rovaldi’s eligibility for the continuation coverage, or (iii) the date Mr. Rovaldi becomes eligible for substantially equivalent healthcare coverage through another source, (c) acceleration of vesting of an aggregate of 19,800 shares of the Company’s common stock subject to his unvested restricted stock units, effective upon the expiration of the Consulting Period and (d) reimbursement of outplacement services used by Mr. Rovaldi (up to $10,000) for a period not to exceed one year following the Separation Date. The Separation Agreement also contains confidentiality, non-competition, non-disparagement and non-solicitation covenants and a release of claims by Mr. Rovaldi.

The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement, which is filed as Exhibit 10.2